SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
TEL AVIV, ISRAEL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc" or the "Company") today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.3 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 6,500,000 ordinary shares (or pre-funded warrants in lieu of ordinary shares) at a price to the public of $0.20 per share (less $0.001 in exercise price per pre-funded warrant). The Company intends to use the net proceeds from this offering for working capital.
以色列特拉维夫,2023年8月10日(环球社)--本公司(纳斯达克股票代码:SPRC)(以下简称“本公司”或“本公司”)今天宣布,在扣除承销折扣和本公司应支付的其他估计费用之前,为本公司确定承销公开发行股票的价格,预计总收益约为130万美元。基本发售包括6,500,000股普通股(或代替普通股的预筹资权证),向公众出售的价格为每股0.2美元(每份预筹资权证的行使价减去0.001美元)。本公司拟将本次发行所得款项净额用作营运资金。
In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. If this option is exercised in full, the total gross proceeds of the offering including over-allotments are expected to be approximately $1.5 million before deducting underwriting discounts, commissions and offering expenses.
此外,公司还授予Aegis Capital Corp.为期45天的选择权,购买普通股数量最多为此次发行普通股数量的15%,以弥补超额配售(如果有)。如果全面行使这一选择权,在扣除承销折扣、佣金和发售费用之前,包括超额配售在内的发售总收益预计约为150万美元。
The offering is expected to close on August 14, 2023, subject to the satisfaction of customary closing conditions.
此次发行预计将于2023年8月14日完成,前提是满足惯常的完成条件。
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
宙斯盾资本公司(Aegis Capital Corp.)是此次发行的唯一账簿管理人。
This offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333- 269839) declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 23, 2023. A preliminary prospectus supplement and accompanying shelf prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC's website located at Electronic copies of the preliminary prospectus supplement and the accompanying shelf prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC and that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
此次发售是根据美国证券交易委员会(美国证券交易委员会)于2023年2月23日宣布生效的F-3表格(第333-269839号)中的有效搁置登记声明而进行的。描述建议发售条款的初步招股说明书补充文件和随附的搁置招股说明书已提交给美国证券交易委员会,并可在美国证券交易委员会的网站上下载,电子副本为初步招股说明书附录的电子版,随附的搁置招股说明书可通过以下方式获得:联系宙斯盾资本公司,关注:辛迪加部门,美洲大道1345号,New York,27 Floth,New York,NY 10105,电子邮件:syndicate@aegiscap.com,或电话:(212)813101010。在投资本次发行之前,有兴趣的各方应全文阅读招股说明书副刊及随附的招股说明书以及本公司已向美国证券交易委员会提交的并通过引用并入该招股说明书副刊及随附的招股说明书的其他文件,这些文件提供了有关本公司及本次发行的更多信息。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新闻稿不应构成出售要约或征求购买要约,也不应在任何州或司法管辖区出售这些证券,在这些州或司法管辖区,根据任何州或司法管辖区的证券法,在注册或获得资格之前,此类要约、征求或出售将是非法的。
About SciSparc Ltd. (Nasdaq: SPRC):
关于本公司(纳斯达克市场代码:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.
SciSparc有限公司是一家专业的临床阶段制药公司,由一支经验丰富的高级管理人员和科学家团队领导。本组织的重点是创建和加强以大麻类药物为基础的技术和资产组合。在这一重点的基础上,该公司目前正在从事以下基于THC和/或非精神活性CBD的药物开发计划:用于治疗抽动症的SCI-110,用于治疗阿尔茨海默病和躁动的SCI-110;用于治疗疼痛的SCI-160;以及用于治疗自闭症和癫痫持续状态的SCI-210。该公司还拥有一家子公司的控股权,该子公司的业务重点是在亚马逊市场上销售大麻种子的油基产品。
For Further Information please refer to information available on the Company's website:
欲了解更多信息,请参阅公司网站上的信息:
Investor Contact:
投资者联系方式:
IR@scisparc.com
邮箱:ir@scisparc.com
Tel: +972-3-6167055
电话:+9723-6167055
Cautionary Note Regarding Forward-Looking Statements
有关前瞻性陈述的注意事项
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses use of proceeds from the offering, and the closing of the offering. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs or projections will be achieved, and actual results may differ materially from what is expressed in, or indicated by, the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on May 1, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
本新闻稿包含私人证券诉讼改革法和其他证券法所指的“前瞻性陈述”。诸如“预期”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计”等词语以及此类词语的类似表达或变体旨在识别前瞻性陈述。例如,该公司在讨论发行所得资金的使用和发行结束时使用前瞻性陈述。前瞻性陈述不是历史事实,而是基于管理层目前的预期、信念和预测,其中许多从本质上讲是不确定的。这些期望、信念和预测是真诚地表达出来的。然而,不能保证管理层的期望、信念或预测一定会实现,实际结果可能与前瞻性陈述中所表达的或所表明的大不相同。前瞻性陈述会受到风险和不确定因素的影响,这些风险和不确定性可能会导致实际业绩或结果与前瞻性陈述中所表达的大不相同。有关影响公司的风险和不确定性的更详细描述,请参考公司不时提交给美国证券交易委员会(“美国证券交易委员会”)的报告,包括但不限于公司于2023年5月1日提交的20-F表格年度报告中详细说明的风险。前瞻性陈述仅在陈述发表之日起发表。除非适用的证券法要求,否则公司没有义务更新前瞻性陈述,以反映实际结果、后续事件或情况、假设的变化或影响前瞻性信息的其他因素的变化。如果公司确实更新了一项或多项前瞻性陈述,则不应推断公司将对该前瞻性陈述或其他前瞻性陈述进行额外的更新。
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. SciSparc is not responsible for the contents of third-party websites.
为方便起见,我们提供了网站的参考资料和链接,本新闻稿中不包含此类网站所包含的信息作为参考。本网站不对第三方网站的内容负责。